Official US Poverty Rate Declined in 2023, but More People Faced Economic Hardship
The arguably better official measure of US poverty says the poor are getting poorer.
Read more...The arguably better official measure of US poverty says the poor are getting poorer.
Read more...Two economists depict degrowth studies as analytically weak and advocating political infeasible ideas.
Read more...An attempt by the Wall Street Journal to mine data on immigration falls short by not providing strong enough caveats.
Read more...How bad incentives and funders’ love of glitz lead to poor scientific research outcomes and demotivated academics.
Read more...Schemes to boost birth rates to bolster growth are generally ineffective and more important, miss the real problem.
Read more...More evidence that the current level of advanced economy secondary market trading is bad for economic health.
Read more...Services are two-thirds of the economy; as long as they’re firm, the economy will plug along just fine, even as manufacturing stalled
Read more...Election statistical models performed poorly in the US this year. That’s to be expected when faced with tail risk events.
Read more...ZOMG, VoxEU starts with the premise that censorship is of course warranted, but finds current implementations have not worked well.
Read more...Influential studies from the VA St. Louis take a broad view of long Covid. Not every expert agrees with the approach.
Read more...Israel ‘s economy is buckling due to its campaign against Palestinians. But despite what may be irreparable damage, it is not turning back.
Read more...A recent report from Pitchbook commits data crimes in attempting to depict private equity management of healthcare companies as benign.
Read more...The FTC targets surveillance pricing, which is privacy-risking data harvesting used to charge higher prices.
Read more...Communities ravaged by neoliberal capitalism want real change. Candidates like Biden make Trump look more able to deliver it.
Read more...More evidence that US drug price curbs are unlikely to be harming pharmaceutical innovation
Read more...